SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesmarket

SYNCS.L (SYNCS.L) News

Track canonical SquawkNews coverage tagged to SYNCS.L, SYNCS.L. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 1 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol SYNCS.L Asset market Sector Markets 90 days 1 Updated Sep 21, 2026, 06:03 AM UTC Open live news feed
M Syncona portfolio company Beacon's gene therapy shows positive Phase II/III results Syncona Limited announced that its portfolio company, Beacon Therapeutics, has delivered positive topline results from its Phase II/III pivotal VISTA study for laru-zova, a gene therapy for X-linked retinitis pigmentosa. EQUITY | Sep 21, 2026, 06:03 AM UTC